WEBSITE BSE:541540 NSE: SOLARA Inc. Year: 2017 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:58
Solara Active Pharma Sciences Ltd manufactures, produces, strategies, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The enterprise gives APIs for a anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, nesthetics, anthelmintic, anti-arrhythmic agent, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic...Read More
Solara Active Pharma Sciences Ltd manufactures, produces, strategies, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The enterprise gives APIs for a anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, nesthetics, anthelmintic, anti-arrhythmic agent, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antigout agent, antihistamine, antihyperlipoproteinemic, antimalarial, antipsychotic, antitubercular, antitussive, antiulcerative, anxiolytic, bile acid analogue, continual alcoholism, continual kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, calcimimetic agent, cardiovascular agent, relevant frightened system agent, lipid regulating agent, loop diuretic, muscarinic agonist, neuromuscular, OAB remedy, phenylalanine reducer, healing of stroke, tardive dyskinesia, remedy of glaucoma and hyperphosphatemia, tropical anti-infective, and sort-II diabetes therapeutic classes. It also offers agreement studies and manufacturing offerings for APIs, which include contract improvement and manufacturing, analytical services, impurity synthesis, and profiling. In addition, the organisation exports its merchandise. It operates inside the Asia Pacific, Europe, North America, South America, and across the world. The employer was previously known as SSL Pharma Sciences Ltd and changed its name to Solara Active Pharma Sciences Ltd in March 2017. Solara Active Pharma Sciences Ltd was founded in 2017 and is based in Chennai, India. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹2300 Cr.
Stock P/E 4259.6
P/B 1.9
Current Price ₹477.5
Book Value ₹ 257.6
Face Value 10
52W High ₹734.2
Dividend Yield 0%
52W Low ₹ 422.9
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 | 349 |
| Other Income | 1 | 0 | 2 | 1 | 0 | 1 | 6 | 1 | 0 | 0 |
| Total Income | 426 | 212 | 301 | 364 | 347 | 302 | 279 | 320 | 314 | 349 |
| Total Expenditure | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 | 312 |
| Operating Profit | 39 | -161 | 11 | 42 | 62 | 59 | 51 | 58 | 35 | 37 |
| Interest | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 | 22 |
| Depreciation | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 26 |
| Exceptional Income / Expenses | -5 | -63 | -122 | 0 | 0 | 0 | 0 | 0 | 0 | -7 |
| Profit Before Tax | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 | -10 | -17 |
| Provision for Tax | 0 | 0 | 89 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 | -17 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 | -17 |
| Adjusted Earnings Per Share | -4.4 | -70.5 | -65.4 | -3.3 | 2 | 2 | -0.5 | 2.4 | -2.3 | -3.9 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 521 | 1387 | 1322 | 1617 | 1268 | 1444 | 1289 | 1284 | 1255 |
| Other Income | 2 | 12 | 28 | 29 | 20 | 23 | 5 | 8 | 7 |
| Total Income | 523 | 1399 | 1349 | 1646 | 1288 | 1466 | 1294 | 1292 | 1262 |
| Total Expenditure | 458 | 1166 | 1062 | 1231 | 1188 | 1310 | 1384 | 1077 | 1081 |
| Operating Profit | 65 | 233 | 287 | 415 | 100 | 156 | -90 | 215 | 181 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 96 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 98 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -3 | 0 | -190 | 0 | -7 |
| Profit Before Tax | 6 | 68 | 115 | 222 | -91 | -45 | -488 | 1 | -18 |
| Provision for Tax | -0 | 1 | 0 | 0 | -33 | -23 | 79 | 0 | 0 |
| Profit After Tax | 6 | 67 | 115 | 221 | -58 | -22 | -567 | 1 | -18 |
| Adjustments | -6 | -8 | 0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | 0 | 60 | 115 | 221 | -58 | -22 | -567 | 1 | -18 |
| Adjusted Earnings Per Share | 0.1 | 21.3 | 39.3 | 56.8 | -14.9 | -5.7 | -145.3 | 0.1 | -4.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -0% | 0% | -1% | 0% |
| Operating Profit CAGR | 0% | 29% | -6% | 0% |
| PAT CAGR | 0% | 0% | -61% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -11% | 13% | -19% | NA% |
| ROE Average | 0% | -16% | -7% | -2% |
| ROCE Average | 6% | -3% | 1% | 4% |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 764 | 956 | 1086 | 1589 | 1525 | 1500 | 934 | 1094 |
| Minority's Interest | 4 | 4 | 4 | 4 | 2 | 2 | 3 | 3 |
| Borrowings | 243 | 225 | 233 | 155 | 283 | 235 | 106 | 114 |
| Other Non-Current Liabilities | 72 | 119 | 101 | 52 | 16 | -18 | 66 | 77 |
| Total Current Liabilities | 738 | 656 | 730 | 789 | 1063 | 1101 | 1243 | 944 |
| Total Liabilities | 1821 | 1960 | 2153 | 2588 | 2890 | 2821 | 2351 | 2232 |
| Fixed Assets | 1063 | 1189 | 1368 | 1356 | 1332 | 1340 | 1266 | 1191 |
| Other Non-Current Assets | 150 | 123 | 113 | 174 | 319 | 293 | 285 | 312 |
| Total Current Assets | 608 | 648 | 672 | 1058 | 1239 | 1188 | 788 | 729 |
| Total Assets | 1821 | 1960 | 2153 | 2588 | 2890 | 2821 | 2351 | 2232 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 46 | 76 | 56 | 198 | 46 | 9 | 8 |
| Cash Flow from Operating Activities | 49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 |
| Cash Flow from Investing Activities | -85 | -116 | -359 | -106 | -243 | -81 | -4 | -37 |
| Cash Flow from Financing Activities | 68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 |
| Net Cash Inflow / Outflow | 31 | 27 | -20 | 142 | -151 | -38 | -0 | -4 |
| Closing Cash & Cash Equivalent | 46 | 76 | 56 | 198 | 46 | 9 | 8 | 4 |
| # | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.14 | 21.28 | 39.34 | 56.79 | -14.89 | -5.68 | -145.26 | 0.13 |
| CEPS(Rs) | 14.92 | 53.71 | 71.63 | 84.65 | 13.83 | 22.77 | -118.69 | 24.79 |
| DPS(Rs) | 0 | 4.59 | 1.83 | 6.42 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 285.37 | 303.81 | 338.18 | 406.5 | 390.13 | 383.8 | 238.67 | 271.04 |
| Core EBITDA Margin(%) | 11.99 | 15.92 | 19.63 | 23.87 | 6.31 | 9.27 | -7.38 | 16.07 |
| EBIT Margin(%) | 5.94 | 10.82 | 14.59 | 18.92 | -1.25 | 3.13 | -29.74 | 8.99 |
| Pre Tax Margin(%) | 1.12 | 4.88 | 8.69 | 13.7 | -7.18 | -3.1 | -37.89 | 0.04 |
| PAT Margin (%) | 1.15 | 4.84 | 8.66 | 13.69 | -4.6 | -1.54 | -43.99 | 0.04 |
| Cash Profit Margin (%) | 7.67 | 10.83 | 15.79 | 20.41 | 4.26 | 6.16 | -35.97 | 7.77 |
| ROA(%) | 0.33 | 3.55 | 5.57 | 9.34 | -2.13 | -0.78 | -21.93 | 0.02 |
| ROE(%) | 0.78 | 8.32 | 12.48 | 17.23 | -3.75 | -1.47 | -46.64 | 0.05 |
| ROCE(%) | 2.22 | 10.38 | 11.73 | 15.34 | -0.67 | 1.79 | -17.29 | 6.07 |
| Receivable days | 183.92 | 72.56 | 71.15 | 80.18 | 140.08 | 129.77 | 125.38 | 95.97 |
| Inventory Days | 131.48 | 52.85 | 68.16 | 64.87 | 125.26 | 143.29 | 129.95 | 96.33 |
| Payable days | 420.15 | 144.29 | 140.33 | 132.36 | 163.35 | 134.61 | 140.3 | 163.63 |
| PER(x) | 0 | 18.15 | 10.38 | 22.63 | 0 | 0 | 0 | 3820.42 |
| Price/Book(x) | 0 | 1.27 | 1.21 | 3.16 | 1.57 | 0.79 | 1.44 | 1.89 |
| Dividend Yield(%) | 0 | 1.19 | 0.45 | 0.5 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.17 | 1.11 | 1.39 | 3.35 | 2.66 | 1.51 | 1.81 | 2.21 |
| EV/Core EBITDA(x) | 9.4 | 6.61 | 6.41 | 13.07 | 33.72 | 13.9 | -25.96 | 13.21 |
| Net Sales Growth(%) | 0 | 166.17 | -4.68 | 22.33 | -21.56 | 13.83 | -10.73 | -0.4 |
| EBIT Growth(%) | 0 | 384.74 | 28.46 | 58.7 | -105.17 | 385.97 | -947.28 | 130.09 |
| PAT Growth(%) | 0 | 1024.35 | 70.7 | 93.29 | -126.33 | 61.83 | -2448.13 | 100.1 |
| EPS Growth(%) | 0 | 0 | 84.84 | 44.36 | -126.21 | 61.86 | -2458.13 | 100.09 |
| Debt/Equity(x) | 0.83 | 0.63 | 0.72 | 0.38 | 0.67 | 0.67 | 1.07 | 0.71 |
| Current Ratio(x) | 0.82 | 0.99 | 0.92 | 1.34 | 1.17 | 1.08 | 0.63 | 0.77 |
| Quick Ratio(x) | 0.57 | 0.66 | 0.54 | 0.97 | 0.62 | 0.57 | 0.34 | 0.44 |
| Interest Cover(x) | 1.23 | 1.82 | 2.48 | 3.62 | -0.21 | 0.5 | -3.65 | 1 |
| Total Debt/Mcap(x) | 0 | 0.5 | 0.59 | 0.12 | 0.43 | 0.85 | 0.75 | 0.32 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 30.49 | 30.49 | 37.27 | 37.27 | 37.23 | 37.94 | 42.01 | 42.01 | 42 | 42 |
| FII | 16.62 | 15.8 | 14 | 14.25 | 14.67 | 14.63 | 14.25 | 13.58 | 11.98 | 11.59 |
| DII | 1.76 | 2.98 | 2.83 | 3.38 | 3.19 | 2.62 | 2.63 | 2.69 | 3.65 | 3.75 |
| Public | 51.14 | 50.74 | 45.9 | 45.1 | 44.91 | 44.81 | 41.11 | 41.72 | 42.37 | 42.66 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.1 | 1.1 | 1.79 | 1.79 | 1.79 | 1.82 | 2.02 | 2.02 | 2.02 | 2.02 |
| FII | 0.6 | 0.57 | 0.67 | 0.68 | 0.7 | 0.7 | 0.69 | 0.65 | 0.58 | 0.56 |
| DII | 0.06 | 0.11 | 0.14 | 0.16 | 0.15 | 0.13 | 0.13 | 0.13 | 0.18 | 0.18 |
| Public | 1.84 | 1.83 | 2.2 | 2.17 | 2.16 | 2.15 | 1.98 | 2.01 | 2.04 | 2.05 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3.6 | 3.6 | 4.8 | 4.8 | 4.81 | 4.81 | 4.82 | 4.82 | 4.82 | 4.82 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
